Company Filing History:
Years Active: 2013-2021
Title: Riccardo Dolcetti: Innovator in Monoclonal Antibody Research
Introduction
Riccardo Dolcetti is a prominent inventor based in Cordenons, Italy. He has made significant contributions to the field of immunology, particularly in the development of monoclonal antibodies. With a total of 2 patents, Dolcetti's work has the potential to impact the treatment of various lymphoproliferative disorders.
Latest Patents
Dolcetti's latest patents include the "Anti-BARF1 monoclonal antibody," which relates to a new monoclonal antibody targeting the BARF1 protein. This invention aims to provide therapeutic options for conditions associated with this protein. Another notable patent is the "Idiotypic vaccine," which concerns the use of recombinant clonotypic immunoglobulins as a vaccine for treating HCV-related and non-HCV-related lymphoproliferations. This invention utilizes immunogenic proteins derived from specific segments of immunoglobulin light chains from patients with lymphoproliferations.
Career Highlights
Throughout his career, Riccardo Dolcetti has worked with various organizations, including Uniquest Pty Limited and Areta International S.r.l. His experience in these companies has allowed him to advance his research and contribute to innovative solutions in the medical field.
Collaborations
Dolcetti has collaborated with notable professionals in his field, including Antonio Rosato and Riccardo Turrini. These collaborations have enriched his research and expanded the scope of his inventions.
Conclusion
Riccardo Dolcetti's contributions to monoclonal antibody research and immunology are noteworthy. His innovative patents and collaborations highlight his commitment to advancing medical science. His work continues to pave the way for new therapeutic approaches in treating lymphoproliferative disorders.